drug

upadacitinib tartrate ER

Marketedupdated 3mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $6.0B

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.

indications

investigational

IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(19)

approval · 19

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

→

view all 19 catalysts →

Trials studying upadacitinib tartrate ER

phase4A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritisrecruitingn=100
phase4Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritisnot yet recruitingn=200

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 26, 2027

271 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (74)

Mar 9, 2038method-of-use (U-3624)US 11564922
Mar 9, 2038method-of-use (U-3624)US 11564922
Mar 9, 2038method-of-use (U-3624)US 11564922
Mar 9, 2038method-of-use (U-3341)US 11607411
Mar 9, 2038method-of-use (U-3341)US 11607411
Mar 9, 2038method-of-use (U-3341)US 11607411
Oct 17, 2036formulationUS 10202393
Oct 17, 2036formulationUS 10344036
Oct 17, 2036formulationUS 10519164
Oct 17, 2036method-of-use (U-3298)US 10550126
Oct 17, 2036method-of-use (U-3255)US 10597400
Oct 17, 2036formulationUS 10730883
Oct 17, 2036compositionUS 10981923
Oct 17, 2036compositionUS 10981923
Oct 17, 2036compositionUS 10981923
Oct 17, 2036formulationUS 10981924
Oct 17, 2036formulationUS 10981924
Oct 17, 2036method-of-use (U-3298)US 10995095
Oct 17, 2036compositionUS 11186584
Oct 17, 2036compositionUS 11186584
Oct 17, 2036compositionUS 11186584
Oct 17, 2036formulationUS 11198697
Oct 17, 2036formulationUS 11198697
Oct 17, 2036formulationUS 11198697
Oct 17, 2036method-of-use (U-3275)US 11365198
Oct 17, 2036method-of-use (U-3371)US 11512092
Oct 17, 2036method-of-use (U-3371)US 11524964
Oct 17, 2036method-of-use (U-3255)US 11535624
Oct 17, 2036method-of-use (U-3298)US 11535625
Oct 17, 2036method-of-use (U-3298)US 11535626
Oct 17, 2036compositionUS 11661425
Oct 17, 2036compositionUS 11661425
Oct 17, 2036compositionUS 11661425
Oct 17, 2036compositionUS 11680069
Oct 17, 2036compositionUS 11680069
Oct 17, 2036compositionUS 11680069
Oct 17, 2036compositionUS 11718627
Oct 17, 2036compositionUS 11718627
Oct 17, 2036compositionUS 11718627
Oct 17, 2036method-of-use (U-3298)US 11767326
Oct 17, 2036method-of-use (U-3298)US 11767326
Oct 17, 2036compositionUS 11773105
Oct 17, 2036compositionUS 11773105
Oct 17, 2036compositionUS 11773105
Oct 17, 2036method-of-use (U-3371)US 11773106
Oct 17, 2036formulationUS 11780847
Oct 17, 2036method-of-use (U-3371)US 11780848
Oct 17, 2036formulationUS 11787815
Oct 17, 2036method-of-use (U-3255)US 11795175
Oct 17, 2036method-of-use (U-3298)US 11976077
Oct 17, 2036method-of-use (U-3946)US 11993605
Oct 17, 2036method-of-use (U-3487)US 11993606
Oct 17, 2036formulationUS 12077545
Oct 17, 2036formulationUS 12077545
Oct 17, 2036formulationUS 12077545
Oct 17, 2036formulationUS 12091415
Oct 17, 2036formulationUS 12103933
Oct 17, 2036formulationUS 12110297
Oct 17, 2036compositionUS 12110298
Oct 17, 2036compositionUS 12110298
Oct 17, 2036compositionUS 12110298
Oct 17, 2036formulationUS 12116373
Oct 17, 2036formulationUS 12134621
Oct 17, 2036method-of-use (U-3945)US 12365689
Oct 17, 2036compositionUS 9951080
Oct 17, 2036compositionUS 9951080
Oct 17, 2036compositionUS 9951080
Oct 17, 2036formulationUS 9963459
Aug 16, 2033compositionUS RE47221
Aug 16, 2033compositionUS RE47221
Aug 16, 2033compositionUS RE47221
Jan 15, 2031compositionUS 89626294.5y
Jan 15, 2031compositionUS 89626294.5y
Jan 15, 2031compositionUS 89626294.5y

FDA exclusivities (13)

Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
Apr 28, 2028I-966Indication (3y)1.8y
Apr 26, 2027I-946Indication (3y)271d
Apr 26, 2027I-946Indication (3y)271d
Apr 26, 2027NPPNew Product (3y)271d
Apr 26, 2027NPPNew Product (3y)271d
Apr 26, 2027I-946Indication (3y)271d
Apr 26, 2027NPPNew Product (3y)271d
May 18, 2026I-919Indication (3y)
May 18, 2026I-919Indication (3y)
May 18, 2026I-919Indication (3y)

News(0)

no news has mentioned this drug yet

brand

Rinvoq

generic

upadacitinib tartrate

MOA

12.1 Mechanism of Action Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In a cell-free isolated enzyme assay, upadacitinib had greater inhibitory potency at JAK1 and JAK2 relative to JAK3 and TYK2. In human leukocyte cellular assays, upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

indication

Vitiligo

phase

marketed

approved

2019-08-16

Data sources

openFDA · ClinicalTrials.gov

last refreshed 8m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

upadacitinib tartrate ER

Marketedupdated 3mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $6.0B

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.

indications

investigational

IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(19)

approval · 19

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

RINVOQ (UPADACITINIB) — FDA approval

upadacitinib tartrate ER

→

view all 19 catalysts →

Trials studying upadacitinib tartrate ER

phase4A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritisrecruitingn=100
phase4Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritisnot yet recruitingn=200

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 26, 2027

271 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (74)

Mar 9, 2038method-of-use (U-3624)US 11564922
Mar 9, 2038method-of-use (U-3624)US 11564922
Mar 9, 2038method-of-use (U-3624)US 11564922
Mar 9, 2038method-of-use (U-3341)US 11607411
Mar 9, 2038method-of-use (U-3341)US 11607411
Mar 9, 2038method-of-use (U-3341)US 11607411
Oct 17, 2036formulationUS 10202393
Oct 17, 2036formulationUS 10344036
Oct 17, 2036formulationUS 10519164
Oct 17, 2036method-of-use (U-3298)US 10550126
Oct 17, 2036method-of-use (U-3255)US 10597400
Oct 17, 2036formulationUS 10730883
Oct 17, 2036compositionUS 10981923
Oct 17, 2036compositionUS 10981923
Oct 17, 2036compositionUS 10981923
Oct 17, 2036formulationUS 10981924
Oct 17, 2036formulationUS 10981924
Oct 17, 2036method-of-use (U-3298)US 10995095
Oct 17, 2036compositionUS 11186584
Oct 17, 2036compositionUS 11186584
Oct 17, 2036compositionUS 11186584
Oct 17, 2036formulationUS 11198697
Oct 17, 2036formulationUS 11198697
Oct 17, 2036formulationUS 11198697
Oct 17, 2036method-of-use (U-3275)US 11365198
Oct 17, 2036method-of-use (U-3371)US 11512092
Oct 17, 2036method-of-use (U-3371)US 11524964
Oct 17, 2036method-of-use (U-3255)US 11535624
Oct 17, 2036method-of-use (U-3298)US 11535625
Oct 17, 2036method-of-use (U-3298)US 11535626
Oct 17, 2036compositionUS 11661425
Oct 17, 2036compositionUS 11661425
Oct 17, 2036compositionUS 11661425
Oct 17, 2036compositionUS 11680069
Oct 17, 2036compositionUS 11680069
Oct 17, 2036compositionUS 11680069
Oct 17, 2036compositionUS 11718627
Oct 17, 2036compositionUS 11718627
Oct 17, 2036compositionUS 11718627
Oct 17, 2036method-of-use (U-3298)US 11767326
Oct 17, 2036method-of-use (U-3298)US 11767326
Oct 17, 2036compositionUS 11773105
Oct 17, 2036compositionUS 11773105
Oct 17, 2036compositionUS 11773105
Oct 17, 2036method-of-use (U-3371)US 11773106
Oct 17, 2036formulationUS 11780847
Oct 17, 2036method-of-use (U-3371)US 11780848
Oct 17, 2036formulationUS 11787815
Oct 17, 2036method-of-use (U-3255)US 11795175
Oct 17, 2036method-of-use (U-3298)US 11976077
Oct 17, 2036method-of-use (U-3946)US 11993605
Oct 17, 2036method-of-use (U-3487)US 11993606
Oct 17, 2036formulationUS 12077545
Oct 17, 2036formulationUS 12077545
Oct 17, 2036formulationUS 12077545
Oct 17, 2036formulationUS 12091415
Oct 17, 2036formulationUS 12103933
Oct 17, 2036formulationUS 12110297
Oct 17, 2036compositionUS 12110298
Oct 17, 2036compositionUS 12110298
Oct 17, 2036compositionUS 12110298
Oct 17, 2036formulationUS 12116373
Oct 17, 2036formulationUS 12134621
Oct 17, 2036method-of-use (U-3945)US 12365689
Oct 17, 2036compositionUS 9951080
Oct 17, 2036compositionUS 9951080
Oct 17, 2036compositionUS 9951080
Oct 17, 2036formulationUS 9963459
Aug 16, 2033compositionUS RE47221
Aug 16, 2033compositionUS RE47221
Aug 16, 2033compositionUS RE47221
Jan 15, 2031compositionUS 89626294.5y
Jan 15, 2031compositionUS 89626294.5y
Jan 15, 2031compositionUS 89626294.5y

FDA exclusivities (13)

Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
Apr 26, 2031ODE-481Orphan Drug (7y)4.7y
Apr 28, 2028I-966Indication (3y)1.8y
Apr 26, 2027I-946Indication (3y)271d
Apr 26, 2027I-946Indication (3y)271d
Apr 26, 2027NPPNew Product (3y)271d
Apr 26, 2027NPPNew Product (3y)271d
Apr 26, 2027I-946Indication (3y)271d
Apr 26, 2027NPPNew Product (3y)271d
May 18, 2026I-919Indication (3y)
May 18, 2026I-919Indication (3y)
May 18, 2026I-919Indication (3y)

News(0)

no news has mentioned this drug yet

brand

Rinvoq

generic

upadacitinib tartrate

MOA

indication

Vitiligo

phase

marketed

approved

2019-08-16

Data sources

openFDA · ClinicalTrials.gov

last refreshed 8m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

upadacitinib tartrate ER

🐶 often sniffed alongside

indications

all catalysts(19)

Trials studying upadacitinib tartrate ER

Patent cliff

patents (74)

FDA exclusivities (13)

News(0)

Report a data issue

comments(0)

upadacitinib tartrate ER

🐶 often sniffed alongside

indications

all catalysts(19)

Trials studying upadacitinib tartrate ER

Patent cliff

patents (74)

FDA exclusivities (13)

News(0)

Report a data issue

comments(0)